Back to News
Market Impact: 0.2
Sun Pharma Reports Two-Year LEQSELVI Data In Severe Alopecia Areata
Source: Nasdaq
Healthcare & Biotech
Sun Pharmaceutical reported two-year safety and efficacy data for LEQSELVI (deuruxolitinib) in adults with severe alopecia areata at the 2026 EADV Congress. The update supports the drug's clinical profile, but the article provides no efficacy figures, safety details, regulatory milestones, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk